Cargando…

Adverse health consequences in COPD patients with rapid decline in FEV(1 )- evidence from the UPLIFT trial

BACKGROUND: The rate of decline in forced expiratory volume in 1 second (FEV(1)) is representative of the natural history of COPD. Sparse information exists regarding the associations between the magnitude of annualised loss of FEV(1 )with other endpoints. METHODS: Retrospective analysis of UPLIFT(®...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kesten, Steven, Celli, Bartolome, Decramer, Marc, Liu, Dacheng, Tashkin, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190346/ https://www.ncbi.nlm.nih.gov/pubmed/21955733 http://dx.doi.org/10.1186/1465-9921-12-129

Ejemplares similares

Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT(®) Trial
por: Halpin, David M. G., et al.
Publicado: (2011)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Exacerbation frequency and course of COPD
por: Halpin, David MG, et al.
Publicado: (2012)

Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial
por: Celli, Bartolomé R., et al.
Publicado: (2016)

Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009)

Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease
por: Celli, Bartolome R, et al.
Publicado: (2012)

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD
por: Tashkin, Donald P, et al.
Publicado: (2014)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
por: Tashkin, Donald P., et al.
Publicado: (2018)

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial
por: Tashkin, Donald P, et al.
Publicado: (2015)

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials
por: Cooper, Christopher B, et al.
Publicado: (2011)

A blood and bronchoalveolar lavage protein signature of rapid FEV(1) decline in smoking-associated COPD
por: DiLillo, Katarina M., et al.
Publicado: (2023)

Risk factors for FEV(1) decline in mild COPD and high-risk populations
por: Chen, Shujing, et al.
Publicado: (2017)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Comparison of the variability of the annual rates of change in FEV(1) determined from serial measurements of the pre- versus post-bronchodilator FEV(1) over 5 years in mild to moderate COPD: Results of the lung health study
por: Tashkin, Donald P, et al.
Publicado: (2012)

Finding the Best Thresholds of FEV(1) and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study
por: Almagro, Pere, et al.
Publicado: (2014)

Predictive Value of Combining Inflammatory Biomarkers and Rapid Decline of FEV(1) for COPD in Chinese Population: A Prospective Cohort Study
por: Wang, Yunxia, et al.
Publicado: (2019)

Lower FEV(1) in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV(1), total IgE levels, and TSLP genotypes
por: Masuko, Hironori, et al.
Publicado: (2011)

Accelerated FEV(1) decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients
por: Whittaker, Hannah R., et al.
Publicado: (2021)

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
por: Rabe, Klaus F., et al.
Publicado: (2020)

Annual decline rate in FEV1s in community-dwelling older adults diagnosed with mild to moderate COPD
por: Rosso, Aldana, et al.
Publicado: (2022)

Systematic review of the evidence relating FEV(1 )decline to giving up smoking
por: Lee, Peter N, et al.
Publicado: (2010)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
por: Bikov, Andras, et al.
Publicado: (2020)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
por: Halpin, David MG, et al.
Publicado: (2017)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting
por: Whittaker, Hannah R, et al.
Publicado: (2019)

Challenges and Pitfalls of Using Repeat Spirometry Recordings in Routine Primary Care Data to Measure FEV(1) Decline in a COPD Population
por: Whittaker, Hannah R, et al.
Publicado: (2021)

COPD assessment test and FEV(1): do they predict oxygen uptake in COPD?
por: Carvalho-Jr, Luiz Carlos S, et al.
Publicado: (2018)

COPD-associated miR-145-5p is downregulated in early-decline FEV(1) trajectories in childhood asthma
por: Tiwari, Anshul, et al.
Publicado: (2020)

Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement
por: Jones, Paul, et al.
Publicado: (2012)

Rapid FEV(1)/FVC Decline Is Related With Incidence of Obstructive Lung Disease and Mortality in General Population
por: Choi, Kwang Yong, et al.
Publicado: (2022)

Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
por: Morjaria, Jaymin B., et al.
Publicado: (2017)

Machine learning for screening of at-risk, mild and moderate COPD patients at risk of FEV(1) decline: results from COPDGene and SPIROMICS
por: Wang, Jennifer M., et al.
Publicado: (2023)

Uplifting Runaways
por: Luest, Severin
Publicado: (2019)

Uplifting magnets...
Publicado: (1973)

Systematic review with meta-analysis of the epidemiological evidence relating FEV(1) decline to lung cancer risk
por: Fry, John S, et al.
Publicado: (2012)

Obstructive sleep apnoea accelerates FEV(1) decline in asthmatic patients
por: Wang, Tsai-Yu, et al.
Publicado: (2017)

Inflammatory and immunological profiles in patients with COPD: relationship with FEV (1) reversibility
por: Queiroz, Cleriston Farias, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9doucemcmhq6lhg75u6fs4jvkl